MCID: MLG069
MIFTS: 46

Malignant Hypertension

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Malignant Hypertension

MalaCards integrated aliases for Malignant Hypertension:

Name: Malignant Hypertension 12 15 17 72
Hypertension, Malignant 44
Hypertension Malignant 55

Classifications:



External Ids:

Disease Ontology 12 DOID:10824
MeSH 44 D006974
NCIt 50 C3118
SNOMED-CT 68 70272006
UMLS 72 C0020540

Summaries for Malignant Hypertension

Disease Ontology : 12 A hypertension that is characterized by rapid onset of extremely high blood pressure.

MalaCards based summary : Malignant Hypertension, also known as hypertension, malignant, is related to malignant hypertensive renal disease and malignant renovascular hypertension. An important gene associated with Malignant Hypertension is REN (Renin), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Nifedipine and Losartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 75 A hypertensive emergency is high blood pressure with potentially life-threatening symptoms and signs... more...

Related Diseases for Malignant Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 1
Hypertension, Essential 2 Hypertension, Essential 3
Hypertension, Essential 4 Hypertension, Essential 5
Hypertension, Essential 6 Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 309)
# Related Disease Score Top Affiliating Genes
1 malignant hypertensive renal disease 33.8 REN EDN1
2 malignant renovascular hypertension 32.6 REN EDN1
3 malignant secondary hypertension 32.3 REN EDN1
4 hypertensive retinopathy 31.3 REN ACE
5 hypertensive encephalopathy 31.0 REN ACE
6 nephrosclerosis 30.5 AGTR1 ADAMTS13 ACE
7 hypertension, diastolic 30.5 REN ACE
8 cardiac tamponade 30.4 REN NPPB
9 acute kidney failure 30.3 REN NPPA ADAMTS13
10 iga glomerulonephritis 30.3 REN AGTR1 ACE
11 malignant essential hypertension 30.3 REN ACE
12 hypokalemia 30.1 REN ACE
13 vascular disease 30.1 REN EDN1 ACE
14 hypertensive nephropathy 30.0 AGTR1 ACE
15 conn's syndrome 29.8 REN NPPA AGTR1
16 end stage renal failure 29.7 AGTR1 AGT ACE
17 arteriosclerosis 29.7 EDN1 ADM ACE
18 renal tuberculosis 29.5 REN EDN1
19 syndrome of inappropriate antidiuretic hormone 29.5 NPPB NPPA ACE
20 pericardial effusion 29.4 REN NPPB NPPA
21 nonarteritic anterior ischemic optic neuropathy 29.3 EDN1 AGTR1 ACE
22 connective tissue disease 29.2 EDN1 ADAMTS13 ACE
23 microvascular complications of diabetes 3 29.1 AGTR1 AGT ACE
24 anuria 28.9 REN AGTR1 AGT ACE
25 cerebrovascular disease 28.8 REN AGTR1 ADM ACE
26 vesicoureteral reflux 1 28.8 REN AGTR1 AGT
27 fibromuscular dysplasia 28.7 REN AGTR1 AGT ACE
28 renal hypertension 28.4 REN NPPB EDN1 AGTR1 ADM ACE
29 pulmonary edema 28.4 REN NPPB NPPA EDN1 ACE
30 renal artery disease 28.4 REN AGTR1 AGT ACE
31 renal dysplasia 28.3 REN AGTR1 AGT ACE
32 renovascular hypertension 28.2 REN NPPA EDN1 AGTR1 ADM ACE
33 coronary artery anomaly 28.0 NPPB NPPA EDN1 AGTR1 ACE
34 diabetes mellitus 27.6 REN EDN1 AGTR1 AGT ACE
35 pulmonary hypertension 27.5 REN NPPB NPPA EDN1 ADM ACE
36 pre-eclampsia 27.2 REN NPPA EDN1 AGTR1 AGT ADM
37 congestive heart failure 27.0 REN NPPB NPPA EDN1 AGTR1 ADM
38 arteries, anomalies of 27.0 REN NPPB EDN1 AGTR1 AGT ACE
39 kidney disease 26.9 REN NPPB NPPA EDN1 AGTR1 AGT
40 heart disease 26.8 REN NPPB NPPA EDN1 AGTR1 ADM
41 hypertension, essential 26.8 REN NPPB NPPA EDN1 AGTR1 AGT
42 hemolytic uremic syndrome, atypical 1 11.4
43 renal artery obstruction 10.5 REN ACE
44 orthostatic proteinuria 10.4 REN ACE
45 left bundle branch hemiblock 10.4 NPPB ACE
46 thrombotic microangiopathy 10.4
47 aortic valve insufficiency 10.4 NPPB ACE
48 vasculogenic impotence 10.3 NPPA ACE
49 glomerulonephritis 10.3
50 pseudohyperkalemia, familial, 2, due to red cell leak 10.3 REN ACE

Graphical network of the top 20 diseases related to Malignant Hypertension:



Diseases related to Malignant Hypertension

Symptoms & Phenotypes for Malignant Hypertension

MGI Mouse Phenotypes related to Malignant Hypertension:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 ACE ADM AGT AGTR1 EDN1 NPPA
2 homeostasis/metabolism MP:0005376 9.76 ACE ADAMTS13 ADM AGT AGTR1 EDN1
3 muscle MP:0005369 9.35 ADM AGT EDN1 NPPA REN
4 renal/urinary system MP:0005367 9.17 ACE ADM AGT AGTR1 EDN1 NPPA

Drugs & Therapeutics for Malignant Hypertension

Drugs for Malignant Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifedipine Approved Phase 4 21829-25-4 4485
2
Losartan Approved Phase 4 114798-26-4 3961
3
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
4
Atenolol Approved Phase 4 29122-68-7 2249
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
7
Amlodipine Approved Phase 4 88150-42-9 2162
8
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
9
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
10 Hormones Phase 4
11 Tocolytic Agents Phase 4
12 Neurotransmitter Agents Phase 4
13 Sodium Chloride Symporter Inhibitors Phase 4
14 Adrenergic beta-1 Receptor Antagonists Phase 4
15 Natriuretic Agents Phase 4
16 Adrenergic beta-Antagonists Phase 4
17 diuretics Phase 4
18 Peripheral Nervous System Agents Phase 4
19 Angiotensin II Type 1 Receptor Blockers Phase 4
20 Giapreza Phase 4
21 Adrenergic Antagonists Phase 4
22 Adrenergic Agents Phase 4
23 Angiotensin Receptor Antagonists Phase 4
24 Sympatholytics Phase 4
25 Anti-Arrhythmia Agents Phase 4
26 Angiotensinogen Phase 4
27 Autonomic Agents Phase 4
28 Antihypertensive Agents Phase 4
29
protease inhibitors Phase 4
30 HIV Protease Inhibitors Phase 4
31 Angiotensin-Converting Enzyme Inhibitors Phase 4
32 Vasodilator Agents Phase 4
33 Calcium, Dietary Phase 4
34 calcium channel blockers Phase 4
35
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616 46835353
36
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
37 Nigella Phase 3
38 Hypoglycemic Agents Phase 3
39
Diazoxide Approved Phase 2 364-98-7 3019
40
Choline Approved, Nutraceutical Phase 2 62-49-7 305
41 Gastrointestinal Agents Phase 2
42 Lipid Regulating Agents Phase 2
43 Hypolipidemic Agents Phase 2
44 Nootropic Agents Phase 2
45 Antimetabolites Phase 2
46
Bevacizumab Approved, Investigational Phase 1 216974-75-3
47 Angiogenesis Inhibitors Phase 1
48 Angiogenesis Modulating Agents Phase 1
49 Antineoplastic Agents, Immunological Phase 1
50
Testosterone Approved, Experimental, Investigational 481-30-1, 58-22-0 6013 10204

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
2 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
3 Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients Completed NCT02995954 Phase 4 Perindopril/Amlodipine
4 Effects of Angiotensin Converting Enzyme Inhibitors on Peritoneal Protein Loss and Solute Transport in Peritoneal Dialysis Patients Completed NCT01575652 Phase 4
5 Effect of Nigella Sativa Seed Extract on the Blood Pressure of Elderly With Hypertension Unknown status NCT01393054 Phase 3 Nigella sativa
6 Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent Unknown status NCT00376870 Phase 3 Pioglitazone;Placebo
7 A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Diazoxide Choline in Non-Diabetic Hypertriglyceridemic Subjects Completed NCT00696475 Phase 2 Diazoxide choline;Diazoxide choline;Diazoxide choline;Placebo
8 Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial Unknown status NCT02672995 Phase 1 bevacizumab
9 Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial Unknown status NCT01834365
10 Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study. Unknown status NCT02099903
11 Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy. Unknown status NCT01870310
12 Single Incision Laparoscopy Completed NCT00616616
13 Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies and Urgencies Completed NCT02924805
14 Assessment of Renal and Cervical Artery DysplasIA Completed NCT02884141
15 Correlates of Nonadherence to Hypertension Treatment in an Inner-City Minority Population Completed NCT00005240
16 Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma Completed NCT01810744
17 Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine Headache: A Randomized Control Trial Completed NCT03479060
18 Serum Androgen Levels as a Marker for the Severity of Preeclampsia Active, not recruiting NCT03744988
19 A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort Not yet recruiting NCT03755726
20 Incidence and Causes of Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Malignant Hypertension

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Captopril
Diazoxide
Enalapril
Enalapril Maleate
Enalaprilat
Fenoldopam
Fenoldopam
Fenoldopam Mesylate
Hydralazine
Hydralazine Hydrochloride
Labetalol
Labetalol hydrochloride
Mecamylamine
Mecamylamine hydrochloride
Minoxidil
nebivolol
Phenoxybenzamine
Phenoxybenzamine Hydrochloride
Phentolamine
Phentolamine Mesylate
Sodium Nitroprusside
trimethaphan camsylate

Cochrane evidence based reviews: hypertension, malignant

Genetic Tests for Malignant Hypertension

Anatomical Context for Malignant Hypertension

MalaCards organs/tissues related to Malignant Hypertension:

41
Kidney, Heart, Brain, Eye, Testes, Liver, Endothelial

Publications for Malignant Hypertension

Articles related to Malignant Hypertension:

(show top 50) (show all 1942)
# Title Authors PMID Year
1
Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. 9 38
18332284 2008
2
The renin-angiotensin system in malignant hypertension revisited: plasma renin activity, microangiopathic hemolysis, and renal failure in malignant hypertension. 9 38
17679041 2007
3
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. 9 38
17485026 2007
4
Angiotensin-converting enzyme i/d polymorphism in patients with malignant hypertension. 9 38
15655381 2005
5
The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. 9 38
14769441 2004
6
Recovery from renal failure in malignant hypertension associated with primary aldosteronism: effect of an ACE inhibitor. 9 38
11861963 2002
7
Angiotensin-converting enzyme gene I/D polymorphism in malignant hypertension. 9 38
10855732 2000
8
Plasma adrenomedullin and natriuretic peptides in patients with essential or malignant hypertension. 9 38
10221353 1999
9
The importance of the renin-angiotensin system in cardiovascular disease. 9 38
9655650 1998
10
The Tsukuba hypertensive mouse (transgenic mouse carrying human genes for both renin and angiotensinogen) as a model of human malignant hypertension: development of lesions and morphometric analysis. 9 38
9504863 1998
11
Nephrosclerosis and hypertension. 9 38
9356598 1997
12
Malignant hypertension in a patient with primary aldosteronism with elevated active renin concentration. 9 38
9372330 1997
13
Antihypertensive therapy reduces increased plasma levels of adrenomedullin and brain natriuretic peptide concomitant with regression of left ventricular hypertrophy in a patient with malignant hypertension. 9 38
10968202 1996
14
Hyperrenin-hyperaldosterone-dependent malignant hypertension in polyarteritis nodosa. 9 38
7903825 1993
15
Blood pressure, angiotensin-converting enzyme (ACE) inhibitors, and the kidney. 9 38
1580276 1992
16
Angiotensin converting enzyme inhibitors in cardiovascular and renal disease in Africans: a review. 9 38
1908620 1991
17
Hyperhomocysteinemia: a trigger for complement-mediated TMA? 38
31401947 2019
18
Comment on: "Serous retinal detachment in preeclampsia and malignant hypertension". 38
31278383 2019
19
Elevated Plasma Renin Activity Caused by Accelerated-malignant Hypertension in a Patient with Aldosterone-producing Adenoma Complicated with Renal Insufficiency. 38
31292373 2019
20
Posterior reversible encephalopathy syndrome in stroke-prone spontaneously hypertensive rats on high-salt diet. 38
29350576 2019
21
Patterns of renal disease: A 30-year renal biopsy study at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, South Africa. 38
31266574 2019
22
Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. 38
30809002 2019
23
Serous retinal detachment in preeclampsia and malignant hypertension. 38
31089238 2019
24
Systemic Sclerosis with Focus on Scleroderma Renal Crisis. 38
31209194 2019
25
Takayasu arteritis, malignant hypertension and severe left ventricular hypertrophy. 38
30861323 2019
26
Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. 38
31420192 2019
27
Factors associated with adverse outcomes from cardiovascular events in the kidney transplant population: an analysis of national discharge data, hospital characteristics, and process measures. 38
31138156 2019
28
Hypertensive Choroidopathy Revealing Malignant Hypertension in a Young Patient. 38
30893276 2019
29
Fundoscopy and malignant hypertension. 38
30395318 2019
30
Etiology and Outcomes of Thrombotic Microangiopathies. 38
30862697 2019
31
The exaggerated salt-sensitive response in hypertensive transgenic rats (TGR mRen-2) fostered by a normotensive female. 38
30531845 2019
32
The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management. 38
30871486 2019
33
Malignant hypertension: not quite an obsolete diagnosis yet. 38
30640869 2019
34
Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. 38
30160657 2019
35
A Case of Rheumatoid Arthritis Presenting with Renal Thrombotic Microangiopathy Probably due to a Combination of Chronic Tacrolimus Arteriolopathy and Severe Hypertension. 38
30963011 2019
36
Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics. 38
30891033 2019
37
Takayasu arteritis: differential diagnosis in a teenager with severe acute kidney injury - a case report. 38
30638252 2019
38
Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Population-Based Cohort Study). 38
30477805 2019
39
Inherited risk plus prenatal insult caused malignant dysfunction in mesenteric arteries in adolescent SHR offspring. 38
31017969 2019
40
Optical coherence tomography angiography findings in malignant hypertensive retinopathy. 38
30652771 2019
41
Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature. 38
30510913 2018
42
Renal involvement in antiphospholipid syndrome. 38
29730854 2018
43
Hospitalizations for Cardiovascular Disease After Liver Transplantation in the United States. 38
29544033 2018
44
20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. 38
30054426 2018
45
Therapy of scleroderma renal crisis: State of the art. 38
30005860 2018
46
Multiple Sclerosis Drug Fingolimod Induces Thrombotic Microangiopathy in Deoxycorticosterone Acetate/Salt Hypertension. 38
30354753 2018
47
The case report of capillary leakage syndrome secondary to malignant hypertension. 38
30142799 2018
48
An elderly man with gastric cancer, Saint's triad and Heyde's syndrome. 38
30540734 2018
49
Forced Diuresis and Expedient Blood Pressure Control in the Management of Quetiapine Induced Neuroleptic Malignant Syndrome: A Case Report. 38
30087734 2018
50
Balloon angioplasty of renal artery stenosis due to Takayasu arteritis in a 2-year-old child. 38
29784504 2018

Variations for Malignant Hypertension

Expression for Malignant Hypertension

Search GEO for disease gene expression data for Malignant Hypertension.

Pathways for Malignant Hypertension

GO Terms for Malignant Hypertension

Cellular components related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 REN NPPB NPPA EDN1 AGT ADM
2 extracellular space GO:0005615 9.23 REN NPPB NPPA EDN1 AGT ADM

Biological processes related to Malignant Hypertension according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.87 NPPB EDN1 AGT
2 response to hypoxia GO:0001666 9.84 NPPA EDN1 ADM
3 response to lipopolysaccharide GO:0032496 9.83 REN EDN1 ADM
4 negative regulation of cell growth GO:0030308 9.79 NPPB NPPA AGT
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.78 EDN1 AGTR1 AGT ADM
6 female pregnancy GO:0007565 9.75 NPPA AGT ADM
7 kidney development GO:0001822 9.73 REN AGTR1 AGT ACE
8 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.7 AGTR1 AGT
9 positive regulation of endothelial cell migration GO:0010595 9.7 EDN1 AGT
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.7 EDN1 AGT
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 EDN1 AGT
12 regulation of cardiac conduction GO:1903779 9.69 NPPA AGT
13 positive regulation of protein tyrosine kinase activity GO:0061098 9.69 AGT ACE
14 cell-cell signaling GO:0007267 9.68 EDN1 AGT
15 blood vessel remodeling GO:0001974 9.68 AGT ACE
16 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.68 EDN1 AGTR1
17 positive regulation of reactive oxygen species metabolic process GO:2000379 9.68 AGTR1 AGT
18 positive regulation of cardiac muscle hypertrophy GO:0010613 9.67 EDN1 AGT
19 positive regulation of blood vessel diameter GO:0097755 9.67 AGT ADM
20 positive regulation of blood pressure GO:0045777 9.67 AGT ACE
21 vasoconstriction GO:0042310 9.65 EDN1 AGT
22 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.65 AGTR1 AGT
23 positive regulation of cellular protein metabolic process GO:0032270 9.65 AGTR1 AGT
24 response to muscle stretch GO:0035994 9.64 NPPA EDN1
25 cell growth involved in cardiac muscle cell development GO:0061049 9.64 NPPA AGT
26 positive regulation of urine volume GO:0035810 9.63 NPPB EDN1
27 peptide catabolic process GO:0043171 9.63 ADAMTS13 ACE
28 positive regulation of heart rate GO:0010460 9.63 NPPA EDN1 ADM
29 low-density lipoprotein particle remodeling GO:0034374 9.62 AGTR1 AGT
30 amyloid-beta metabolic process GO:0050435 9.62 REN ACE
31 receptor guanylyl cyclase signaling pathway GO:0007168 9.61 NPPB NPPA
32 cGMP biosynthetic process GO:0006182 9.6 NPPB NPPA
33 angiotensin maturation GO:0002003 9.59 REN ACE
34 artery smooth muscle contraction GO:0014824 9.58 EDN1 AGT
35 regulation of blood vessel diameter GO:0097746 9.58 NPPB AGTR1 ACE
36 positive regulation of cholesterol esterification GO:0010873 9.57 AGTR1 AGT
37 body fluid secretion GO:0007589 9.56 NPPB EDN1
38 positive regulation of NAD(P)H oxidase activity GO:0033864 9.55 AGTR1 AGT
39 regulation of renal sodium excretion GO:0035813 9.54 AGTR1 AGT
40 positive regulation of renal sodium excretion GO:0035815 9.54 NPPB EDN1 AGT
41 regulation of blood volume by renin-angiotensin GO:0002016 9.52 REN AGT
42 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.51 AGTR1 AGT
43 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.5 AGTR1 AGT ACE
44 regulation of renal output by angiotensin GO:0002019 9.49 AGT ACE
45 regulation of vasoconstriction GO:0019229 9.46 EDN1 AGTR1 AGT ACE
46 renin-angiotensin regulation of aldosterone production GO:0002018 9.43 REN AGTR1 AGT
47 regulation of blood vessel size GO:0050880 9.26 NPPB NPPA EDN1 AGT
48 regulation of blood pressure GO:0008217 9.1 REN NPPB NPPA EDN1 AGT ACE

Molecular functions related to Malignant Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 REN NPPB NPPA EDN1 ADM
2 hormone receptor binding GO:0051427 9.26 NPPB NPPA
3 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE
4 hormone activity GO:0005179 9.02 NPPB NPPA EDN1 AGT ADM

Sources for Malignant Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....